Active — Not RecruitingNot Applicable

Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

United States80 participantsStarted 2011-02

Plain-language summary

The goal of this study is to learn if using a non-invasive therapy called "neurofeedback training" can help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
✓. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
✓. Pain score \>/= 4 on a 0-10 numeric pain scale and/or grade 3 neuropathic symptoms according to the National Cancer Institute's 4 point grading scale.
✓. Pain must be related to chemotherapy (in the opinion of the treating physician).
✓. Patients must have had neuropathic pain for a minimum of 3 months.
✓. No plans to change pain medication regimen during the course of the study.
✓. Off active chemotherapy treatment for minimum of 3 months.
✓. Hormonal (e.g., tamoxifen or arimidex, etc.) and targeted (tarceva and avastin, etc.) therapies allowed as long as they will be continued during the course of the study.

Exclusion criteria

✕. Patients who are taking any antipsychotic medications.
✕. Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy.
✕. Patients who have ever been diagnosed with bipolar disorder or schizophrenia.

What they're measuring

Effects of Individualized Electroencephalogram (EEG) Biofeedback Treatment Regimen on Perceptions of Chemotherapy-Induced Neuropathic Pain

Timeframe: 10 weeks

Trial details

NCT IDNCT01278225

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-04-01

View on ClinicalTrials.gov More Pain trials